Pliant Therapeutics, Inc. $PLRX Stake Boosted by Monaco Asset Management SAM

Monaco Asset Management SAM grew its stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) by 135.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,938,747 shares of the company’s stock after purchasing an additional 1,116,054 shares during the quarter. Monaco Asset Management SAM’s holdings in Pliant Therapeutics were worth $2,365,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. FNY Investment Advisers LLC bought a new position in shares of Pliant Therapeutics during the third quarter valued at approximately $37,000. Jump Financial LLC bought a new position in shares of Pliant Therapeutics during the second quarter valued at approximately $30,000. Canada Pension Plan Investment Board bought a new position in shares of Pliant Therapeutics during the second quarter valued at approximately $36,000. Engineers Gate Manager LP boosted its position in shares of Pliant Therapeutics by 139.4% during the second quarter. Engineers Gate Manager LP now owns 31,423 shares of the company’s stock worth $36,000 after buying an additional 18,300 shares during the period. Finally, Rangeley Capital LLC grew its holdings in Pliant Therapeutics by 20.4% in the 2nd quarter. Rangeley Capital LLC now owns 60,220 shares of the company’s stock worth $70,000 after buying an additional 10,220 shares in the last quarter. 97.30% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Wall Street Zen raised Pliant Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 19th. Piper Sandler decreased their price objective on Pliant Therapeutics from $4.00 to $3.00 and set an “overweight” rating for the company in a report on Thursday, March 12th. Canaccord Genuity Group decreased their price objective on Pliant Therapeutics from $4.00 to $3.00 and set a “hold” rating for the company in a report on Friday, March 13th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Pliant Therapeutics in a report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $3.00.

Pliant Therapeutics Price Performance

PLRX opened at $1.26 on Monday. The company has a market capitalization of $78.02 million, a price-to-earnings ratio of -0.68 and a beta of 1.20. Pliant Therapeutics, Inc. has a 1-year low of $1.09 and a 1-year high of $1.95. The business has a 50 day moving average price of $1.25 and a two-hundred day moving average price of $1.30.

Pliant Therapeutics (NASDAQ:PLRX) last released its earnings results on Monday, May 11th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.04. Equities analysts expect that Pliant Therapeutics, Inc. will post -1.37 EPS for the current fiscal year.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems.

The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).